Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
Multivalent Trident Aptamers for Molecular Recognition
The USPTO published patent application US20260098270A1 by McMaster University on April 9, 2026. The application covers multivalent trident aptamers comprising a branched linker molecule with 2-3 variable arms connected to a root, designed for enhanced affinity and avidity in target molecular recognition. The aptamers have applications in pharmaceutical, diagnostic, and therapeutic fields.
siRNA Compositions Targeting CD33 Gene for Neuroinflammatory Disease Treatment
The USPTO published patent application US20260098269A1 covering single- or double-stranded interfering RNA (siRNA) molecules targeting the Siglec-5 (CD33) gene, pharmaceutical compositions containing these molecules, and methods for treating neuroinflammatory diseases including Alzheimer's disease. The application claims specific nucleoside modifications, internucleoside linkage modifications, branched siRNA configurations (di-branched, tri-branched, tetra-branched), 5′ phosphorus stabilizing moieties, hydrophobic moieties, and CNS delivery methods.
Selective Astrocytic MAGL Inactivation for Alzheimer's Disease Treatment
USPTO published patent application US20260098268A1 for compositions and methods treating Alzheimer's disease through selective astrocytic MAGL inactivation via AAV-mediated gene silencing. Inventors: Chu Chen, Jian Zhang. Filed September 29, 2023. The invention targets neuroinflammation reduction by selectively inactivating MAGL in astrocytes rather than globally, minimizing adverse effects from neuronal 2-AG degradation disruption.
Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes
Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes
CRISPR Methods for Treating Microbial Infections - SNIPR Biome
SNIPR Biome ApS filed USPTO patent application US20260098260A1 covering CRISPR-based methods for treating microbial infections including sepsis, septicemia, SIRS, and septic shock. The application also covers controlling microbiologically influenced corrosion and biofouling in industrial or domestic systems using CRISPR technology. Inventors include Morten Sommer, Virginia Martinez, Eric van der Helm, Jakob Krause Haaber, Ana de Santiago Torio, Christian Grøndahl, and Jasper Clube.
Compositions and Methods for Identification of VHH Antibodies That Bind a Target Antigen
The USPTO published patent application US20260098255A1 for Broad Institute's VHH antibody identification methods. The application covers compositions and methods for identifying VHH antibodies that bind target antigens. The application (No. 19415305) was filed December 10, 2025, and published April 9, 2026.
Anti-SIRPalpha Antibody for Tumor Treatment
USPTO published patent application US20260098102A1 by National University Corporation Kobe University on April 9, 2026. The application discloses an anti-SIRPα monoclonal antibody that binds human SIRPα to inhibit the SIRPα/CD47 interaction for use as an anti-tumor agent. The invention is classified under C07K 16/28 and related peptide technology categories.
Anti-IL-36R Monoclonal Antibody and Use Thereof for Inflammatory Disease Treatment
USPTO published patent application US20260098101A1 from QYUNS THERAPEUTICS CO., LTD. covering an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody for inflammatory disease treatment. The application was filed on December 4, 2025. The antibody comprises six complementarity determining regions with amino acid sequences specified in the filing, and the applicant claims superior neutralizing activity compared to Spesolimab at the cellular level.
IL-4R and TSLP Inhibitors, Inflammatory Treatment Patent Application
USPTO published patent application US20260098100A1 covering antigen binding moieties that inhibit IL-4R and TSLP pathways for inflammatory disease treatment. The application names Miguel A. Sanjuan, Sheila Gujrathi, and Ryan P. Sullivan as inventors and was filed November 10, 2025. The disclosed invention blocks IL4-IL-4R and TSLP-TSLPR interactions, targeting the same pathways addressed by approved drugs Dupilumab and Tezepelumab.
Anti-sIL7R Antibody Therapy for Treating Autoimmune Diseases
The USPTO published patent application US20260098099A1 assigned to the Board of Regents of the University of Texas System, covering methods and compositions for anti-soluble interleukin-7 receptor (sIL7R) antibodies for treating autoimmune diseases including multiple sclerosis, lupus nephritis, type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. The application was filed on August 10, 2025.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
720 changes in last 7 days
Latest high priority updates
141 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.